Tien-Chun Yang

Dr. Tien-Chun Yang

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ERElham Rastegari
Elham Rastegari
YHYu Jer Hsiao
Yu Jer Hsiao
WLWei-Yi Lai
Wei-Yi Lai
YLYun-Hsien Lai
Yun-Hsien Lai
TYTien-Chun Yang
Tien-Chun Yang
YCYueh Chien
Yueh Chien
The efficient and safe delivery of therapeutic drugs, proteins, and nucleic acids are essential for meaningful therapeutic benefits. The field of nanomedicine shows promising implications in the development of therapeutics by delivering diagnostic and therapeutic compounds. Nanomedicine development has led to significant advances in the design and engineering of nanocarrier systems with supra-molecular structures. Smart mesoporous silica nanoparticles (MSNs), with excellent biocompatibility, tunable physicochemical properties, and site-specific functionalization, offer efficient and high loading capacity as well as robust and targeted delivery of a variety of payloads in a controlled fashion. Such unique nanocarriers should have great potential for challenging biomedical applications, such as tissue engineering, bioimaging techniques, stem cell research, and cancer therapies. However, in vivo applications of these nanocarriers should be further validated before clinical translation. To this end, this review begins with a brief introduction of MSNs properties, targeted drug delivery, and controlled release with a particular emphasis on their most recent diagnostic and therapeutic applications.

1 January 2020 in Acta Biomaterialia
Verified
Journal Article
Open access
TYTien-Chun Yang
Tien-Chun Yang
Chia-Ching ChangChia-Ching Chang
Chia-Ching Chang
AYAliaksandr A. Yarmishyn
Aliaksandr A. Yarmishyn
YMYen-Shiang Mao
Yen-Shiang Mao
YYYi-Ping Yang
Yi-Ping Yang
Shih-Hwa ChiouShih-Hwa Chiou
Shih-Hwa Chiou
Nanodiamonds (NDs) are considered to be relatively safe carbon nanomaterials used for the transmission of DNA, proteins and drugs. The feasibility of utilizing the NDs to deliver CRISPR-Cas9 system for gene editing has not been clearly studied. Therefore, in this study, we aimed to use NDs as the carriers of CRISPR-Cas9 components designed to introduce the mutation in RS1 gene associated with X-linked retinoschisis (XLRS). ND particles with a diameter of 3 nm were functionalized by carboxylation of the surface and covalently conjugated with fluorescent mCherry protein. Two linear DNA constructs were attached to the conjugated mCherry: one encoded Cas9 endonuclease and GFP reporter, another encoded sgRNA and contained insert of HDR template designed to introduce RS1 c.625C>T mutation. Such nanoparticles were successfully delivered and internalized by human iPSCs and mouse retinas, the efficiency of internalization was significantly improved by mixing with BSA. The delivery of ND particles led to introduction of RS1 c.625C>T mutation in both human iPSCs and mouse retinas. Rs1 gene editing in mouse retinas resulted in several pathological features typical for XLRS, such as aberrant photoreceptor structure. To conclude, our ND-based CRISPR-Cas9 delivery system can be utilized as a tool for creating in vitro and in vivo disease models of XLRS. STATEMENT OF SIGNIFICANCE: X-linked retinoschisis (XLRS) is a prevalent hereditary retinal disease, which is caused by mutations in RS1 gene, whose product is important for structural organization of the retina. The recent development of genome editing techniques such as CRISPR-Cas9 significantly improved the prospects for better understanding the pathology and development of treatment for this disease. Firstly, gene editing can allow development of appropriate in vitro and in vivo disease models; secondly, CRISPR-Cas9 can be applied for gene therapy by removing the disease-causative mutation in vivo. The major prerequisite for these approaches is to develop safe and efficient CRISPR-Cas9 delivery system. In this study, we tested specifically modified nanodiamonds for such a delivery system. We were able to introduce Rs1 mutation into the mouse retina and, importantly, observed several XLRS-specific effects.

1 February 2018 in Experimental Cell Research
Verified
Journal Article
Closed access
YWYou-Ren Wu
You-Ren Wu
AWAn-Guor Wang
An-Guor Wang
YCYan-Ting Chen
Yan-Ting Chen
AYAliaksandr A. Yarmishyn
Aliaksandr A. Yarmishyn
WBWaradee Buddhakosai
Waradee Buddhakosai
SCShih-Jen Chen
Shih-Jen Chen

Verified
Journal Article
Open access
PDF file
TYTien-Chun Yang
Tien-Chun Yang
JCJen-Hua Chuang
Jen-Hua Chuang
WBWaradee Buddhakosai
Waradee Buddhakosai
WWWen-Ju Wu
Wen-Ju Wu
CLChen-Ju Lee
Chen-Ju Lee
SCShih-Jen Chen
Shih-Jen Chen
Optic neuropathies, such as glaucoma and Leber’s hereditary optic neuropathy (LHON) lead to retinal ganglion cell (RGC) loss and therefore motivate the application of transplantation technique into disease therapy. However, it is a challenge to direct the transplanted optic nerve axons to the correct location of the retina. The use of appropriate scaffold can promote the proper axon growth. Recently, biocompatible materials have been integrated into the medical field, such as tissue engineering and reconstruction of damaged tissues or organs. We, herein, utilized nano-imprinting to create a scaffold mimicking the in vitro tissue microarchitecture, and guiding the axonal growth and orientation of the RGCs. We observed that the robust, long, and organized axons of human induced pluripotent stem cell (iPSC)-derived RGCs projected axially along the scaffold grooves. The RGCs grown on the scaffold expressed the specific neuronal biomarkers indicating their proper functionality. Thus, based on our in vitro culture system, this device can be useful for the neurophysiological analysis and transplantation for ophthalmic neuropathy treatment.

4 August 2016 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
TYTien-Chun Yang
Tien-Chun Yang
PWPei‐Chun Wu
Pei‐Chun Wu
ICI‐Fang Chung
I‐Fang Chung
JJJhih-Hang Jiang
Jhih-Hang Jiang
MFMing‐Ji Fann
Ming‐Ji Fann
LKLung‐Sen Kao
Lung‐Sen Kao
The pathogenesis of Parkinson's disease (PD) is not completely understood, Zinc (Zn2+) and dopamine (DA) have been shown to involve in the degeneration of dopaminergic cells. By microarray analysis, we identified Gadd45b as a candidate molecule that mediates Zn2+and DA‐induced cell death; the mRNA and protein levels of Gadd45b are increased by Zn2+treatment and raised to an even higher level by Zn2+plus DA treatment. Zn2+plus DA treatment‐induced PC12 cell death was enhanced when there was over‐expression of Gadd45b and was decreased by knock down of Gadd45b. MAPK p38 and JNK signaling was able to cross‐talk with Gadd45b during Zn2+and DA treatment. The synergistic effects of Zn2+and DA on PC12 cell death can be accounted for by an activation of the Gadd45b‐induced cell death pathway and an inhibition of p38/JNK survival pathway. Furthermore, thein vivoresults show that the levels of Gadd45b protein expression and phosphorylation of p38 were increased in the substantia nigra by the infusion of Zn2+/DA in the mouse brain and the level of Gadd45b mRNA is significantly higher in the substantia nigra of male PD patients than normal controls. The novel role of Gadd45b and its interactions with JNK and p38 will help our understanding of the pathogenesis of PD and help the development of future treatments for PD. image Zinc and dopamine are implicated in the degeneration of dopaminergic neurons. We previously demonstrated that zinc and dopamine induced synergistic effects on PC12 cell death. Results from this study show that these synergistic effects can be accounted for by activation of the Gadd45b‐induced cell death pathway and inhibition of the p38/JNK survival pathway. We providein vitroandin vivoevidence to support a novel role for Gadd45b in the pathogenesis of Parkinson's disease.

21 March 2023 in Journal of Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
TYTien-Chun Yang
Tien-Chun Yang
MLMei-Hua Lu
Mei-Hua Lu
WWWei-Jie Wang
Wei-Jie Wang
JCJang-Yi Chen
Jang-Yi Chen
The pathogenesis of hypertension is not fully understood; endothelin 1 (EDN1) is involved in developing essential hypertension. EDN1 can promote vascular smooth muscle cell (VSMC) proliferation or hypertrophy through autocrine and paracrine effects. Proliferating smooth muscle cells in the aorta are 'dedifferentiated' cells that cause increased arterial stiffness and remodeling. Male SHRs had higher aortic stiffness than normal control male WKY rats. Male SHR VSMCs expressed high levels of the EDN1 gene, but endothelial cells did not. Therefore, it is necessary to understand the molecular mechanism of enhanced EDN1 expression in SHR VSMCs. We identified POU2F2 and CEBPB as the main molecules that enhance EDN1 expression in male SHR VSMCs. A promoter activity analysis confirmed that the enhancer region of the Edn1 promoter in male SHR VSMCs was from −1309 to −1279 bp. POU2F2 and CEBPB exhibited an additive role in the enhancer region of the EdnET1 promoter. POU2F2 or CEBPB overexpression sufficiently increased EDN1 expression, and co-transfection with the CEBPB and POU2F2 expression plasmids had additive effects on the activity of the Edn1 promoter and EDN1 secretion level of male WKY VSMCs. In addition, the knockdown of POU2F2 also revealed that POU2F2 is necessary to enhance EDN1 expression in SHR VSMCs. The enhancer region of the Edn1 promoter is highly conserved in rats, mice, and humans. POU2F2 and CEBPB mRNA levels were significantly increased in remodeled human VMSCs. In conclusion, the novel regulation of POU2F2 and CEBPB in VSMCs will help us understand the pathogenesis of hypertension and support the development of future treatments for hypertension.